MAIA Biotechnology, Inc. announced that it has entered into a Securities Purchase Agreement with certain accredited investors to issue 326,939 shares of the Company?s common stock, par value $0.0001 per share and warrants to purchase up to 326,939 shares of Common Stock, at a price per share of $2.034, for an aggregate purchase price of approximately $664,994 on April 22, 2024. The Warrants are exercisable at a price per Share of $2.26, which price represents the greater of the book or market value of the stock on the date the Purchase Agreement was executed, are exercisable commencing six months following issuance and have a term of five years from the initial exercise date. The Shares and the Warrants (and the shares of common stock underlying the Warrants) sold in the Private Placement are being issued as restricted securities as defined in Rule 144 of the Securities Act of 1933, as amended and do not contain any registration rights.